VentureMed Group, a Minnesota-based medical device company developing vessel preparation and access management technologies, has closed a $28 million Series C financing round led by S3 Ventures with participation from existing investor Endeavour Vision.
The funding will strengthen VentureMed’s commercial infrastructure, expand clinical research, and support new product applications for its flagship FLEX Vessel Prep (VP) System, which is used in treating peripheral arterial disease (PAD) and arteriovenous fistulas and grafts (AVF, AVG).
The FLEX system, which has received FDA 510(k) clearance and CE Mark approval, uses proprietary Kinetic Endovascular Micro-incision Creation (KEMIC) technology to create long, precise micro-incisions that enhance luminal gain, minimize vessel trauma, and improve drug uptake. The system has also been granted a CMS HCPCS code (C1600) with transitional pass-through payment in the United States, supporting its adoption across vascular centers.
VentureMed’s FLEX VP System addresses the high recurrence of vessel narrowing and the need for repeat procedures in vascular disease treatment. With over 200 million PAD cases worldwide, the company’s technology aims to deliver better long-term outcomes while reducing the burden on patients and healthcare systems.
The proceeds from the Series C will enable VentureMed to expand its indications, accelerate clinical studies, and bring new vascular access solutions to market globally.
KEY QUOTES:
“As we enter our next phase, we are grateful for the continued support of our existing investors and excited to welcome new partners to the syndicate. This significant financing underscores investor confidence in the FLEX Vessel Prep System and our mission to strengthen VentureMed’s position in global vascular care.”
Denis Harrington, President and CEO, VentureMed Group
“VentureMed is addressing one of the most persistent challenges in vascular access with a technology that is both elegant and transformative. Our partnership reflects a shared mission to bring breakthrough treatments to those who need them most.”
Brian R. Smith, Managing Director, S3 Ventures
“Lesion prep is rapidly becoming one of the most important procedures for improving patient outcomes. The FLEX VP system is leading the way in addressing AV Access interventions. This fundraising is an important milestone as the company advances additional clinical evidence and expanded indications.”
Dr. Ari Kramer, General Surgeon, Spartanburg Medical Center
“The cycle of re-narrowing and repeat procedures in vascular disease places a significant burden on patients and health systems. A technology that reduces the need for reinterventions not only improves outcomes but also aligns with the shift to value-based care. We’re excited to continue supporting VentureMed as it expands access to this important therapy.”
Alexander Schmitz, Partner, Endeavour Vision
